Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research

Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research


Alzheimer's Disease Research
Current Award

Dr. Fan Liao

Fan Liao, Ph.D.

Washington University in St. Louis
St. Louis, MO

Title: Apolipoprotein E Passive Immunotherapy for Alzheimer’s Disease
Non-Technical Title: New Therapeutic Approach for Alzheimer’s Disease via Apolipoprotein E

David M. Holtzman, M.D.
Washington University in St. Louis, School of Medicine

Duration: July 1, 2013 - June 30, 2015
Award Type: Postdoctoral Fellowship
Award Amount: $100,000


One of the main hallmarks of Alzheimer disease (AD) is the presence of beta-amyloid (Abeta) plaque deposits in the brain. The team of Dr. Liao and Holtzman has developed a new passive immunization approach to target apolipoprotein E, a protein that interacts with Abeta to influence its clearance and aggregation, and to reduce the amyloid plaques in the brain. In this project, Dr. Liao will further explore the timing of intervention, the potential side effects, and the underlying mechanism of this approach.


The objective of Dr. Liao’s study is to use the antibodies that target apolipoprotein E (ApoE)—a protein that also is present in amyloid plaques and regulates beta-amyloid (Abeta) metabolism—to test if they can modify the disease-associated Abeta deposits and the associated disease progression. If the antibodies do have a disease-modifying effect, they will further investigate the mechanisms that lead to those modifications.

Using an AD mouse model which recapitulates the development of amyloid plaques in the brain, the laboratory of Drs. Liao and Holtzman recently found that if they give the mice antibodies that neutralize ApoE before they develop plaques, they can slow down the Abeta disease-associated effects on the brain. In the first aim of the current project, Dr. Liao will inject the ApoE antibodies into the animals after they have developed amyloid plaques in the brain and assess the effects by testing their cognitive behavior, intrinsic brain network function, and amyloid plaque load in the brain. Dr. Liao will also monitor for potential side-effects of the antibodies by looking for cerebral amyloid angiopathy (CAA; amyloid deposits in brain vessels), or CAA-associated vessel rupture or bleeding.

In the second aim, Dr. Liao will investigate the mechanisms underlying the effects of the ApoE antibodies. To determine the site of action, Dr. Liao will perform short-term immunization of the mouse with the apoE antibodies and monitor the distribution of apoE and apoE antibodies in the brain and the blood. In addition, the ApoE antibodies will be applied directly into the brain and the removal of the pre-existing plaques will be monitored using two-photon microscopy (a fluorescence imaging technique) in live mice. To determine whether the function of the ApoE antibodies is mediated by microglia (brain immune cells that migrate to areas of inflammation), they will use activated microglia detection antibodies. They will also culture microglia with plaque-containing brain slices to determine whether microglia uptake Abeta plaques by phagocytosis (by engulfing, internalizing, and recycling the plaques).

Previous studies on AD immunization used antibodies that directly targeted Abeta. Although certain types of Abeta immunization approaches have been successful in animal models and are being tested in humans, some have significant side effects. This project is innovative in that Dr. Liao’s team will change the immune target to ApoE, a protein that interacts with Abeta. Since there has been a history of side effects to immunization treatments, the team will determine if there are fewer side effects with their method than with the previous Abeta immunization therapies.

If the proposed experiments show success in amyloid plaque intervention, ApoE passive immunotherapy should be explored as a potential prevention or early-stage treatment for AD.

Investigator Biography:

Dr. Liao is a Postdoctoral Research Associate at the Washington University School of Medicine. She completed her doctoral studies at Washington State University. She joined Dr. David Holtzman’s lab in the year of 2010. Dr. Liao’s research focuses on the regulation of Aβ metabolism by endogenous and exogenous factors.